Literature DB >> 21069929

Cancer: A limited role for dual EGFR and ErbB2 inhibition in cholangiocarcinoma?

Shreeya Nanda.   

Abstract

Entities:  

Year:  2010        PMID： 21069929     DOI： 10.1038/nrgastro.2010.163

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

Authors:  Zichen Zhang; Regina A Oyesanya; Deanna J W Campbell; Jorge A Almenara; Jennifer L Dewitt; Alphonse E Sirica
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425
  1 in total
  2 in total

1.  Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma.

Authors:  Changhe Zhang; Hong Xu; Zhenping Zhou; Ye Tian; Xiaofei Cao; Guochang Cheng; Qinghong Liu
Journal:  Exp Ther Med       Date:  2018-04-05       Impact factor: 2.447

2.  Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.

Authors:  Alice Fraveto; Vincenzo Cardinale; Maria Consiglia Bragazzi; Felice Giuliante; Agostino Maria De Rose; Gian Luca Grazi; Chiara Napoletano; Rossella Semeraro; Anna Maria Lustri; Daniele Costantini; Lorenzo Nevi; Sabina Di Matteo; Anastasia Renzi; Guido Carpino; Eugenio Gaudio; Domenico Alvaro
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.